Cytotoxic Drugs & HPAPI Manufacturing Market by Type of Product

CYTOTOXIC DRUGS AND HPAPI MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global cytotoxic drugs and HPAPI manufacturing market is estimated to grow from USD 11.7 billion in the current year to USD 39.9 billion by 2035, at a CAGR of 11.6% during the forecast period, till 2035.

The market opportunity for cell and gene therapy supply chain software has been distributed across the following segments:

Type of Product

HPAPIs

Highly Potent Finished Dosage Forms

Scale of Operation

Preclinical

Clinical

Commercial

Type of Molecule

Small Molecules

Biologics

Type of Highly Potent Finished Dosage Form

Injectables

Oral Solids

Creams

Others

Key Geographical Regions

North America (US, Canada and Mexico)

Europe (UK, Italy, Germany, France, Spain, and Rest of Europe)

Asia-Pacific (China, India, and Rest of Asia-Pacific)

Rest of the World

CYTOTOXIC DRUGS AND HPAPI MANUFACTURING MARKET: GROWTH AND TRENDS

With advances in clinical pharmacology and oncology research, and the increasing demand for targeted therapies, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become the key focus of researchers and drug manufacturers across the world. It is worth highlighting that 45% of the drugs globally are highly potent leading to specialized HPAPI production. However, manufacturing HPAPIs is a complex process and therefore, there are various challenges associated with the process. The biggest challenge is to inhibit cross-contamination during manufacturing followed by the protection of the environment, workers and everyone across the supply chain. It is equally important to choose the correct containment and protective strategy, inclusive of containment equipment, procedures and PPE. HPAPIs handling generally requires continued investment in the area of safe handling, the need for global guidance and advance technical expertise adding to the challenges in the domain. Therefore, drug developers are actively outsourcing their manufacturing operations.

Understanding the vast potential and positive growth outlook of the contract manufacturing market, the majority of big pharma players are looking to make investments to expand and / or upgrade their current manufacturing facilities. A number of CMOs are investing in new facilities in developing countries such as Japan, China, India and Brazil to avail the benefits of lower manufacturing costs, cheap and skilled labor and supportive regulatory landscapes in these areas. Driven by the overall growth of the anti-cancer therapeutics industry, recent technological advancements and the growing trend of outsourcing, the market is anticipated to witness steady growth in the coming decade.

CYTOTOXIC DRUGS AND HPAPI MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the cytotoxic drugs & HPAPI manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Presently, more than 140 players claim to have the required expertise to offer contract manufacturing services for highly potent compounds, across different scales of operation.

The current market landscape is highly fragmented, featuring the presence of both new entrants and established players across key geographical regions.

Leveraging their expertise, stakeholders are offering contract manufacturing services for a myriad of highly potent compounds; around 70% of the service providers possess analytical testing capability for HPAPIs.

The growing interest in this domain is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to HPAPI and cytotoxic drug manufacturing were inked in the recent past.

In order to meet the rising demand for high potency compounds, CMOs have made elaborate investments to expand their facilities and capacities; this trend is most pronounced in the US, Switzerland and the UK.

The installed global contract manufacturing capacity for HPAPIs is well distributed across different geographies; 80% of the present capacity is installed in facilities owned by very large players.

Antibody Drug Conjugates are one of the most popular classes of highly potent compounds; more than 30 players currently claim to offer contract manufacturing / conjugation services for such biopharmaceuticals.

It is anticipated that the highly potent drug developers are likely to outsource their manufacturing operations, enabling the service based revenues to grow at an annualized rate of 11.6%.

CYTOTOXIC DRUGS & HPAPI MANUFACTURING MARKET: KEY SEGMENTS

HPAPI Segment Occupies the Largest Share of the Cytotoxic Drugs and HPAPI Manufacturing Market

Based on the type of product, the market is segmented into HPAPI and highly potent finished dosage forms. At present, HPAPI segment holds the maximum share of the cytotoxic drugs & HPAPI manufacturing market. This trend is unlikely to change in the near future.

Very Large Players are Likely to Dominate the Cytotoxic Drugs & HPAPI Manufacturing Market During the Forecast Period

Based on the company size, the market is segmented into small, mid-sized, large and very large companies. At present, very large companies hold the maximum share of the cytotoxic drugs & HPAPI manufacturing market. This trend is likely to remain the same in the coming decade.

By Scale of Operation, Commercial Scale is Likely to Dominate the Cytotoxic Drugs and HPAPI Manufacturing Market

Based on scales of operation, the market is segmented into preclinical, clinical and commercial scale. It is worth highlighting that, at present, commercial scale holds a larger share of the cytotoxic drugs and HPAPI manufacturing market. This trend is likely to remain the same in the forthcoming years.

Biologics is the Fastest Growing Segment of the Cytotoxic Drugs and HPAPI Manufacturing Market During the Forecast Period

Based on the type of molecule, the market is segmented into small molecules and biologics. It is worth highlighting that, at present, small molecules dominate the cytotoxic drugs and HPAPI manufacturing market. This is primarily due to the fact the CMOs have invested and expanded their capabilities for highly potent small molecules. It is important to note the demand for highly potent drugs is on the rise therefore the market for biologics is expected to grow at a faster pace in the coming decade.

Oral FDFs are Likely to Dominate the Cytotoxic Drugs and HPAPI Manufacturing Market During the Forecast Period

Based on the type of highly potent finished dosage forms, the market is segmented into injectables, oral solids, creams and other FDFs. It is worth highlighting that, at present, oral FDFs capture the highest share of the cytotoxic drugs and HPAPI manufacturing market. This trend is likely to remain the same in the coming decade owing to the benefits offered by oral formulations, such as cost-efficiency for manufacturers, comfort and ease of use for patients.

Europe Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. The majority of the share is expected to be captured by players based in Europe. This is due to the fact that there are well-established players in this region with considerable installed capacities and capabilities. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Cytotoxic Drugs & HPAPI Manufacturing Market

AbbVie

Cambrex

Catalent

Pfizer CentreOne

Piramal Pharma Solutions

Abzena

Aenova

CARBOGEN AMCIS

Hovione

Lonza

Intas Pharmaceuticals

Scinopharm

STA Pharmaceutical (a WuXi AppTec company)

Syngene

Teva API

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Owner and Director, HPAPI Project Service

Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals

ILC Dover, Vice President, Pharma/Bio Technical Support

Ex-Group Product Manager and Ex-Director-Business Development, Catalent

Business Development Director, CordenPharma

Managing Director, ProJect Pharmaceutics

Ex-Business Head, Formulations and Finished Products, Alphora Research

Ex-Site Head, Piramal Healthcare

Ex-Senior Manager, Business Development, Helsinn

Marketing and Sales Manager, Pharma, Cerbios-Pharma

Ex-Business Development Technician, Idifarma

CYTOTOXIC DRUGS AND HPAPI MANUFACTURING MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cytotoxic drugs and HPAPI manufacturing market, focusing on key market segments, including [A] type of product, [B] company size, [C] scale of operation, [D] type of molecule, [E] type of highly potent finished dosage form and [F] key geographical regions.

Market Landscape: A comprehensive evaluation of companies involved in the contract manufacturing of HPAPI and cytotoxic drugs, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] location of manufacturing facility, [E] area of manufacturing facility, [F] scale of operation, [G] type of product manufactured, [H] type of highly potent finished dosage form, [G] Occupational Exposure Limit, [H] type of molecule manufactured, [H] type of primary packaging system, [I] regulatory certifications / accreditations received and [J] type of service(s) offered.

Company Competitiveness Analysis: A comprehensive competitive analysis of HPAPI and cytotoxic drug contract manufacturers, examining factors, such as [A] supplier strength and [B] service strength.

Company Profiles: In-depth profiles of key industry players offering contract manufacturing services for HPAPI and cytotoxic drugs, focusing on [A] company overviews, [B] HPAPI and cytotoxic drug-related service portfolio, [C] dedicated facilities, [D] recent developments and [E] an informed future outlook.

Partnerships and Collaborations: An analysis of partnerships established in this sector based on relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] scale of operation, [D] type of product, [E] most active players (in terms of number of deals inked) and [F] regional distribution of partnership activity that have been undertaken in cytotoxic drugs and HPAPI manufacturing market.

Recent Expansions: An examination of the different expansion efforts made by the HPAPI and cytotoxic drug contract manufacturers in this field to enhance their manufacturing capabilities. This analysis considers various factors, including the [A] year of expansion, [B] type of expansion, [C] company size, [D] location of headquarters, [E] scale of operation, [F] type of product, [G] location of expanded facility, [H] area of expanded facility, [I] amount invested in expansions, [J] most active players (in terms of number of recent expansions) and [K] geographical distribution.

Capacity Analysis: Estimation of global HPAPI manufacturing capacity, derived from data provided by various stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of [A] company size (small, mid-sized and large), [B] scale of operation (preclinical, clinical and commercial) and [C] key geographical regions (North America, Europe and Asia-Pacific).

Regional Capability Assessment Analysis: A regional capability assessment framework that compares the HPAPI and cytotoxic drug manufacturing capabilities across key geographies, based on several parameters, such as [A] the number of HPAPI and cytotoxic drug contract manufacturers, [B] number of HPAPI and cytotoxic drug manufacturing facilities, [C] number of facility expansions and [D] installed HPAPI capacity in that particular geographical region.

SWOT Analysis: A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry’s evolution.

Case Study: A case study on companies offering manufacturing services for antibody drug conjugate (ADCs). The chapter also highlights the key components of ADCs and the key challenges associated with the manufacturing of these products. Further, the chapter presents a list of players that provide contract manufacturing services for ADCs.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?

Which are the leading companies in this market?

What kind of partnership models are commonly adopted by industry stakeholders?

What are the factors that are likely to influence the evolution of this market?

What is the current and future market size?

What is the CAGR of this market?

How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.

The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs

Complimentary Excel Data Packs for all Analytical Modules in the Report

Free Updated report if the report is 6-12 months old or older